Join the BVPPO Section for this special online CE program from Academy Fellow, Dr. Timothy Hug. Two hours of CE will be offered in the coming weeks: August 26 - 8 PM EST(1 hour) Pediatric Anterior Segment Disease September 25 - 8 PM EST(1 hour) Pediatric Posterior Segment Disease The cost for each course is $25/hour. All Academy members are welcome to attend. Register now at https://bit.ly/3SRn2u9 #fellows #optometry
American Academy Of Optometry’s Post
More Relevant Posts
-
Our latest Whitepaper, 'Navigating the Rare Pediatric Disease Priority Review Voucher Program, Ahead of September 2024', is now available to read and download, https://lnkd.in/g8SdRH9E - The paper, written by Iheoma Anosike, provides useful information relating to The rare pediatric disease designation and RPD PRV program, with important considerations for Sponsors. For support ahead of the upcoming 30 September 2024 sunset date, get in touch to speak with a member of the team www.scendea.com/contact - #whitepaper #drugdevelopment #regulatoryaffairs #pediatricdisease
To view or add a comment, sign in
-
U.S. President Biden signed a bill postponing the sunset date of the rare pediatric disease Priority Review Voucher (PRV) program from September 30, 2024, to December 20, 2024. The bill, the “Continuing Appropriations and Extensions Act, 2025” is a temporary measure to continue the rare pediatric disease PRV program. There are currently other ongoing legislative efforts to renew the program through 2028 and later. We have summarized these proposals here: https://lnkd.in/exn-tcha #PediatricHealth #PriorityReviewVoucher #ContinuingAppropriationsandExtensionsAct2025 Authors: Komal Karnik Nigam, Deborah Cho, and Bryan Walsh.
To view or add a comment, sign in
-
Read our new #NORD, the National Organization for Rare Disorders, report on the rare pediatric disease priority review voucher program, and its ability to spur #raredisease #drugdevelopment.
Today, NORD released a new report detailing the effectiveness of the Rare Pediatric Disease Priority Review Voucher Program, which has helped bring 50+ safe and effective treatments to market. Read it here: https://bit.ly/3y4RrOD Congress MUST reauthorize this vital program by September 30, 2024. If you have not yet taken action, contact your Representative here: https://bit.ly/4bey1VI #RareDisease #RareDiseases #PriorityReviewVoucher #PediatricHealth
To view or add a comment, sign in
-
An insightful read on the Rare Pediatric Disease Priority Review Voucher Program!
Our latest whitepaper, 'Navigating the Rare Pediatric Disease Priority Review Voucher Program Ahead of September 2024', written by Senior Consultant Iheoma Anosike is now available to read and download: https://lnkd.in/g8SdRH9E - This whitepaper discusses the rare pediatric disease priority review voucher (RPD PRV) program which was introduced by the US FDA in 2012 and also provides important considerations for Sponsors ahead of the upcoming 30 September 2024 sunset date. - #whitepaper #drugdevelopment #rarepediatricdisease
To view or add a comment, sign in
-
Our latest whitepaper, 'Navigating the Rare Pediatric Disease Priority Review Voucher Program Ahead of September 2024', written by Senior Consultant Iheoma Anosike is now available to read and download: https://lnkd.in/g8SdRH9E - This whitepaper discusses the rare pediatric disease priority review voucher (RPD PRV) program which was introduced by the US FDA in 2012 and also provides important considerations for Sponsors ahead of the upcoming 30 September 2024 sunset date. - #whitepaper #drugdevelopment #rarepediatricdisease
To view or add a comment, sign in
-
In this short video, Dr. Leslie Gordon, Co-Founder and Medical Director of The Progeria Research Foundation, explains the vital importance of Rare Pediatric Disease PRVs for #progeria and other #RareDiseases. If you have not taken action on this issue, do so here: https://lnkd.in/ettvJA2p
Dr. Leslie Gordon, Progeria Research Foundation, Explains Rare Pediatric Disease PRVs
To view or add a comment, sign in
-
🔑✨ TOP PSORIASIS TAKEAWAYS FROM AUGUST: #PsoriasisAwarenessMonth was packed with updates on psoriatic disease: Alumis Inc.’s ESK-001 phase 3 trial, the impact of green spaces on risk, and apremilast becoming available for pediatric patients. Explore our comprehensive recap to stay informed on these important developments and more. ⬇️ https://lnkd.in/gtmadrk9
To view or add a comment, sign in
-
Get your drug to market 4 months faster with a "Rare Pediatric Disease Priority Review Voucher" but hurry, this program ends September 30, 2024! Refer to FDA’s Draft Guidance on Rare Pediatric Disease Priority Review Vouchers (here: https://lnkd.in/eStfxZSi) for details on what to include in your request. Source (see section 5): https://lnkd.in/ems7aMY3 #RarePediatricDisease #PriorityReviewVoucher #PRV #PediatricDisease #RareDiseases #FDA #Regulations #RegulatoryAffairs
To view or add a comment, sign in
-
As a voice for the rare disease community, a recent op-ed in STAT really hit home for me. The article focuses on how the FDA’s rare pediatric disease priority review voucher program will disappear unless Congress reauthorizes it before September 30. As NORD's Pamela Gavin shares in the byline, more than 30 million Americans live with a rare disease, and nearly half are children – the program disappearing would be a devastating end for patients and their families eagerly waiting for treatment. At Aldevron, we are committed to advocating for individuals with #rarediseases by helping develop the tools to create breakthrough treatments, and we understand how important increased funding and programming is in this often-forgotten space. We must continue to push the government to incentivize #drugdevelopment for rare diseases, ensuring that patients continue to have hope for their future. #PRVs #RareDisease #FDA
To view or add a comment, sign in
-
Boost your clinical trial success with our on-demand webinar on building trust with rare disease patients and accelerating enrollment. This webinar is designed to unveil the essential strategies and practices for fostering trust among rare disease patients, which is pivotal in accelerating clinical trial enrollment. Watch now: https://lnkd.in/gqfzUh3D #ClinicalTrials #RareDiseases #PatientTrust
To view or add a comment, sign in
22,837 followers